JP Morgan Maintains Overweight on Protagonist Therapeutics, Raises Price Target to $37
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Brian Cheng has maintained an Overweight rating on Protagonist Therapeutics (NASDAQ:PTGX) and increased the price target from $34 to $37.

February 28, 2024 | 2:49 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JP Morgan analyst Brian Cheng reaffirmed an Overweight rating on Protagonist Therapeutics and raised the price target from $34 to $37.
The increase in price target by a reputable analyst like Brian Cheng from JP Morgan is a strong positive signal for Protagonist Therapeutics. It suggests confidence in the company's future performance and potential for growth, likely leading to increased investor interest and a positive short-term impact on the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100